We angiographically assessed the vasodilatory effects of vasopressin and oxytocin on the basilar arteries in dogs. Intracisternal bolus injections of vasopressin (100 pmol and 1 nmol) and oxytocin (1 and 10 nmol) produced dose-dependent increases in the internal diameter of the basilar arteries without affecting mean arterial blood pres sure. The maximal dilatations of the basilar arteries in duced by 1 nmol vasopressin and 10 nmol oxytocin were 142.3 ± 19.9 and 136.8 ± 25.5% of the baseline, respec tively. When the same peptides were injected into the vertebral artery, the maximal dilatations were similar, but the duration of response was shorter. Pretreatment with intracisternal injection of 10 /-lmol �-monomethyl-L arginine (L-NMMA), which inhibits the synthesis of nitric oxide from L-arginine, suppressed the vasodilatory re sponses induced by intracisternal injection of vasopressin Abbreviations used: CGRP, calcitonin gene-related peptide; L-NMMA, �-monomethyl-L-arginine.
Current evidence indicates that vasopressin and oxytocin, circulating vasoactive peptides released from the neurohypophysial gland, play a role in reg ulating cerebral as well as peripheral vascular to nus. Regional differences in sensitivity and respon siveness of the vasculature to vasopressin and oxy tocin have been demonstrated in the cerebral and coronary arteries in different animal species (Faraci et aI., 1988; Myers et aI., 1989; Suzuki et aI., 1992) . These peptides reduce resistance of large vessels and increase resistance of small vessels. Vaso pressin-immunoreactive nerve fibers have been identified in the cerebral pial arteries of guinea pigs (Itakura et aI. , 1988) . Such nerve fibers suggest that vasopressin may regulate local cerebral blood flow not only as a circulating hormone, but also as a neurotransmitter.
The in vitro vasodilatory effects of vasopressin and oxytocin are mediated through VI receptors connected to an endothelium-dependent relaxing mechanism (Katusic et aI., 1984 (Katusic et aI., , 1986 ). We con firmed angiographically that intraarterial injections of vasopressin and oxytocin into the vertebral ar tery dilated the major cerebral arteries, including the vertebral basilar arteries as well as the circle of Willis and its main branches (Suzuki et aI., 1992) . Nitric oxide or a closely related factor formed from L-arginine has been strongly implicated as an endo thelium-derived relaxing factor (Ignarro et aI. , 1987; Palmer et aI., 1987 Palmer et aI., , 1988 . In this article we shall refer to endothelium-derived relaxing factor as ni tric oxide. Analogues of L-arginine that inhibit the synthesis of nitric oxide from L-arginine have been developed (Hibbs et aI., 1987; Rees et aI., 1989; Moor et aI., 1990) . �-Monomethyl-L-arginine (L-NMMA), �-nitro-L-arginine, and �-amino-L arginine are representative antagonists that are fre quently used to elucidate the pharmacologic func tions of nitric oxide.
In the present study, we investigated whether the intracisternal injection of vasopressin and oxytocin dilated the basilar arteries via the release of nitric oxide in vivo. We also investigated the differences in the vascular responses obtained by intracisternal and intraarterial injection of vasopressin.
MATERIALS AND METHODS
Mature mongrel dogs of either sex, weighing 8-20 kg, were used in these experiments. All procedures were per formed under general anesthesia with intravenous pento barbital (25 mg/kg). Dogs were intubated, and respiration was controlled through tracheal tubes with room air de livered by a respirator (model B2; Igarashi Ika Kogyo Co., Tokyo, Japan). The ventilation rate (�12 cycles/min) and tidal volume (20 ml/kg) were adjusted to maintain arterial blood gas and pH within physiological limits. In this series, the mean baseline value of Pa02 was 90.0 ± 18.8 mm Hg, Paco2 was 33.0 ± 7.1 mm Hg, and pH was 7.36 ± 0.08. A catheter was placed in the left femoral artery to monitor mean arterial blood pressure. To pre vent dehydration, which elevates the endogenous plasma vasopressin, a slow intravenous infusion of saline solu tion was maintained during the procedure.
Measurement of vascular diameter by angiography
The internal diameter of the basilar artery was deter mined by vertebral angiography. A catheter for angiogra phy was inserted directly into the right vertebral artery just before the foramen of the transverse process of the cervical vertebra (C6) at the base of the neck. A control angiogram was performed using 3.0 ml of 65% iothala mate meglumine at a fixed magnification before the injec tion of the control or test solutions. Then, angiograms were continued periodically (5, 10, 15, 20, 30, 45, 60, 90, 120 min) after the control or test solutions were injected through a no. 22 spinal needle into the cisterna magna or the vertebral artery. A volume of 1.5 ml physiological saline was used as a control solution, and all injected substances, vasopressin, oxytocin, calcitonin gene related peptide (CORP), L-NMMA, or L-arginine, were dissolved in the same amount of physiological saline just before use. The pH of all test solutions except for L-argi nine, an alkaline amino acid, was almost the same as that of the control solution. The vasodilatory effect induced by L-arginine solution that had been neutralized by HCl did not differ from the original effect.
In the investigation of the modulating effects of L-NMMA and/or L-arginine on the vasodilation induced by vasopressin, oxytocin, or CORP, these substances were intracisternally injected 30 min before the adminis tration of each peptide. Injection of solutions into the cisterna magna was done after withdrawing gently the same amount of cerebrospinal fluid to preserve the intra cranial pressure as constant as possible. Care was taken to keep the animals in a head-down position, which en hanced the contact of preparations with the basilar artery.
The middle third of the basilar artery was chosen for quantitative evaluation, and the internal diameters of the J Cereb Blood Flow Metab, Vol. /3, No.2, 1993 basilar arteries were measured by means of a computer ized image analysis system (Macintosh lIcx, Image 1.27; Apple Computer, Cupertino, CA, U.S.A.) as previously reported (Harada et aI., 1990; Satoh et aI., 1991; Suzuki et aI., 1992) . The differences in the internal diameter after injection of peptides and nitric oxide-related substances were compared to determine the effects of these sub stances on vascular activity.
Data are expressed as a percentage of the diameter of the arterial segment before the injection of test sub stances (defined as 100%).
Materials
Synthetic Arg-vasopressin, oxytocin, and human calci tonin gene-related peptide ex (CORPex) were purchased from Peptide Institute (Osaka, Japan). L-NMMA was ob tained from Calbiochem (La Jolla, CA, U.S.A.). L-Argi nine and all other chemicals were reagent grade.
Statistical analysis
Data are expressed as means ± SD. Differences were assessed by analysis of variance, Dunnett's test, and Stu dent's t test. p values of <0.05 were considered statisti cally significant.
RESULTS

Intracisternal injection of vasopressin, oxytocin, and CGRP
The intracisternal injection of saline solution as a control did not produce a significant change in the internal diameter of the basilar arteries (1.7 ± 0.2 mm; n = 5) on the angiogram over 120-min period. After bolus injections of vasopressin (100 pmol and 1 nmol), oxytocin (1 and 10 nmol), and CGRP (100 pmol and 1 nmol), dose-dependent increases in the internal diameter of the basilar arteries were clearly observed ( Fig. O . We selected the middle third of the basilar artery for representative quantitative evaluation.
The maximal dilations induced by 1 nmol of va sopressin, 10 nmol of oxytocin, and 1 nmol of CGRP were 142.3 ± 19.9, 136.8 ± 25.5, and 139. 8 ± 31.5% of the baseline, respectively. Significant di lation persisted for 30, 15, and 20 min. There were no significant differences in mean arterial blood pressure among treatment groups or between con trol baseline and treatment groups (Table O. Effects of L-NMMA and L-arginine on responses to vasopressin, oxytocin, and CGRP Pretreatment with 10 !-Lmol of L-NMMA injected intracisternally 30 min before injection of vaso pressin and oxytocin suppressed the vasodilatory responses induced by intracisternal injections of va sopressin and oxytocin, but the response to CGRP was not inhibited by L-NMMA (Fig. 2) . Typical ver tebral angiograms are shown in Fig. 3 . Intracister nal injection of L-NMMA also inhibited the va sodilatory response to intraarterial injection of va- Vasopressin 1 nmol (7) 0 Oxylocin 10 nmol(7) • Vasopressin 100 pmol (5) • Oxytocin 1 nmol(5) '" Conlrol (5) '" Control (5) � 50 sopressin. When 10 j.Lmol L-NMMA and 100 j.Lmol L-arginine were administered simultaneously, the vasodilatory response to vasopressin was restored.
Effects of L-NMMA and L-arginine on basal diameter of cerebral arteries
Intracisternal injection of L-NMMA produced dose-dependent decreases in the internal diameter of the basilar arteries, while L-arginine produced dose-dependent increases (Fig. 4) . For example, 10 j.Lmol L-NMMA produced vasoconstriction that lasted> 120 min with a maximal decrease in diam eter of 75.7 ± 14.8% of the baseline. A dose of 100 IJ-mol L-arginine produced significant increases in the diameter of the basilar arteries for 45 min, with a maximal increase of 135.8 ± 18.5% of the base line. The vasoconstriction induced by L-NMMA was reversed by the application of a 10-fold concen tration of L-arginine. There were no significant changes in mean arterial blood pressure after the intracisternal injection of L-NMMA or L-arginine.
DISCUSSION
Our results show that intracisternal injections of vasopressin and oxytocin in anesthetized dogs pro-duced dose-dependent dilatations of the internal di ameter of the basilar arteries, as demonstrated by angiography. Intracisternal injection of these pep tides in concentrations up to 1 and 10 nmol was not associated with any significant change in mean ar terial blood pressure. The potency of oxytocin is less than one-tenth that of vasopressin, as deter mined by the measurement of vertebral blood flow (Suzuki et aI. , 1992) . When compared with the re sults previously obtained by intraarterial injection (Suzuki et aI., 1992) , the intracisternal injection of vasopressin or oxytocin produced vasodilation of a similar degree, but of a longer duration. These find ings may explain the ease of diffusion of peptides from the extraluminal side into the vascular wall when there is no barrier such as a tight junction of the endothelium or a slow degradation of peptides in the cerebrospinal fluid as compared with their degradation in serum.
Previous reports suggest that the vasodilatory ef fects of vasopressin and oxytocin are mediated through the endothelium and VI receptors, as has been shown in the canine basilar artery in vitro and in vivo (Katusic et aI. , 1984; Suzuki et aI., 1992) . The intracisternal injection of L-NMMA, an argin- Values are means ± SD (mm Hg). n indicates the number of animals. No significant change is seen in any group. ine analogue that inhibits the activity of the nitric oxide synthase, suppressed the vasodilatory effects of vasopressin and oxytocin. The suppressive effect of L-NMMA on vasopressin's action was reversed by a high concentration of L-arginine, a substrate for the formation of nitric oxide. These observa tions suggest that nitric oxide may be responsible for the vasodilation induced by vasopressin and oxytocin in the major cerebral arteries. However, the vasodilation induced by the intracisternal injec tion of CGRP, which has a potency similar to that of vasopressin, was not affected by pretreatment with L-NMMA. CGRP, a potent vasodilatory neuropep tide involved in the sensory fibers innervating brain vessels (McCulloch et aI., 1986; Saito et aI., 1989) , directly stimulates adenylate cyclase of vascular smooth muscle leading to the accumulation of cy clic AMP (Edvinsson et aI., 1985) and to increases in local cerebral blood flow (Ikegaki et aI., 1989; Suzuki et aI., 1989) . Our results confirmed our ear lier in vitro findings , which in dicated that the cerebral vasodilatory response to CGRP was independent of the formation of nitric oxide.
Recent studies suggest that nitric oxide is synthe sized not only in blood vessels, but also in various tissues such as the central and peripheral nervous system, pituitary gland, adrenal gland, platelets, and fibroblasts (Salvemini et aI., 1989; Bredt et aI., 1990; Radomski et aI., 1990; Kuhn et aI., 199 1) . It has also been suggested that nerve fibers in the vas cular wall and smooth muscle cells in blood vessels are able to synthesize and release nitric oxide (Bredt et aI., 1990; Wood et aI., 1990; Benjamin et aI., 199 1; Mollace et aI., 199 1) . In an immunohisto chemical study, dense staining for nitric oxide syn thase was observed in the endothelium and the an terior cerebral artery of the rat (Bredt et aI., 1990 ), suggesting that nitric oxide can influence the tonus of smooth muscle from different sites such as the endothelium and nerve endings in the adventitia. L-NMMA induced contraction of the canine basilar artery even after the removal of the endothelium (Katusic, 199 1) and blocked the transient vasodila tory responses following transmural electrical stim ulation of nonadrenergic non cholinergic nerves (Toda et aI., 1990; Gonzalez and Estrada, 1991) . When vasopressin is injected from the intraluminal side, nitric oxide release from the endothelium may be the main mediator of vasodilation, but it is un clear which of the sites that store nitric oxide in blood vessels when they are stimulated from the extraluminal side. Intracisternal injection of L NMMA probably suppresses the synthesis of nitric oxide in both the endothelium and the nerve end ings, because it similarly inhibits the vasodilatory activity induced by intraluminal and extraluminal administration of vasopressin.
Our in vivo data revealed that the intracisternal injection of L-NMMA and L-arginine produced sig nificant and long-lasting changes in the diameter of basilar arteries, probably leading to hemodynamic changes in cerebral blood flow. The alterations in vascular diameter we observed in the canine basilar artery were greater than those observed by Faraci (1990) in the rat basilar artery, but were relatively consistent with results obtained by the topical ap plication of these substances to mouse and piglet pial arterioles (Busija et aI., 1989; Rosenblum et aI., 1990) . Our findings are also similar to those of Tanaka et al. (1991) who reported that the intrave nous administration of L-NMMA inhibited nitric ox ide synthesis, significantly reducing the regional blood flow in the cortex and deep brain structures accompanied by an elevation in systemic blood pressure. Our results demonstrate that the intracis ternal injection of vasopressin and oxytocin dilated the canine basilar arteries in vivo. The activity of these peptides appeared to be mediated via the re lease of nitric oxide, because L-NMMA blocked the effects of vasopressin and oxytocin and this block ing effect was reversed by L-arginine. The synthesis and release of nitric oxide in vascular tissue includ ing the endothelium, smooth muscle, and nerve fi bers seem to be essential to the maintenance of the basal cerebral circulation. Further studies are needed to determine how the nitric oxide synthe sized in different parts of the vascular tissue inter acts and how nitric oxide interacts with other vaso active substances like vasopressin and acetylcho line.
